BR112013032108A2 - "composições de peptídeo isolado e usos das referidas composições". - Google Patents

"composições de peptídeo isolado e usos das referidas composições".

Info

Publication number
BR112013032108A2
BR112013032108A2 BR112013032108A BR112013032108A BR112013032108A2 BR 112013032108 A2 BR112013032108 A2 BR 112013032108A2 BR 112013032108 A BR112013032108 A BR 112013032108A BR 112013032108 A BR112013032108 A BR 112013032108A BR 112013032108 A2 BR112013032108 A2 BR 112013032108A2
Authority
BR
Brazil
Prior art keywords
compositions
angioedema
anaphylaxis
asthma
injury
Prior art date
Application number
BR112013032108A
Other languages
English (en)
Other versions
BR112013032108B1 (pt
Inventor
Asrar B Malik
Stephen M Vogel
Uzma Saqib
Yulia A Komarova
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BR112013032108A2 publication Critical patent/BR112013032108A2/pt
Publication of BR112013032108B1 publication Critical patent/BR112013032108B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "composições de peptídeo e métodos para tratar lesão pulmonar, asma, anafilaxia, angioedema, síndromes de permeabilidade vascular sistêmica, e congestão nasal". a invenção refere-se a inibidores peptídicos da interação entre proteína de ligação de extremidades 3 (eb3) e receptor de inositol 1,4,5-trisfosfato tipo 3 (ip3r3). a invenção refere-se também a métodos e materiais para tratar lesão pulmonar, inclusive lesão pulmonar aguda, a qual pode incluir hiperpermeabilidade dos vasos pulmonares, derrame vascular, o desenvolvimento de edema, asma, anafilaxia, angioedema, síndromes de permeabilidade vascular sistêmica, e congestão nasal.
BR112013032108-3A 2011-06-13 2012-06-13 Peptídeos conjugados, usos dos mesmos e de um peptídeo isolado, bem como formulação farmacêutica BR112013032108B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496409P 2011-06-13 2011-06-13
US61/496,409 2011-06-13
PCT/US2012/042118 WO2012174028A2 (en) 2011-06-13 2012-06-13 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Publications (2)

Publication Number Publication Date
BR112013032108A2 true BR112013032108A2 (pt) 2016-11-22
BR112013032108B1 BR112013032108B1 (pt) 2021-10-26

Family

ID=47357694

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032108-3A BR112013032108B1 (pt) 2011-06-13 2012-06-13 Peptídeos conjugados, usos dos mesmos e de um peptídeo isolado, bem como formulação farmacêutica

Country Status (15)

Country Link
US (2) US9248198B2 (pt)
EP (1) EP2717897B1 (pt)
JP (1) JP6042425B2 (pt)
KR (1) KR102042015B1 (pt)
CN (2) CN106188232B (pt)
AU (1) AU2012271781C1 (pt)
BR (1) BR112013032108B1 (pt)
CA (1) CA2838662C (pt)
DK (1) DK2717897T3 (pt)
ES (1) ES2633343T3 (pt)
IL (1) IL229771B (pt)
MX (1) MX349146B (pt)
PL (1) PL2717897T3 (pt)
WO (1) WO2012174028A2 (pt)
ZA (1) ZA201309161B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102042015B1 (ko) * 2011-06-13 2019-11-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법
SG11201706799YA (en) * 2015-03-02 2017-09-28 Univ Illinois Peptides for inhibiting angiogenesis
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
CN110664990B (zh) * 2019-11-07 2021-03-16 江南大学 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用
WO2021211784A2 (en) * 2020-04-15 2021-10-21 Cohbar, Inc. Method of treating coronavirus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CA2545062A1 (en) 2003-11-06 2005-05-26 Research Development Foundation Selective inhibitors of nuclear factor-kb activation and uses thereof
JP4772690B2 (ja) * 2003-12-03 2011-09-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チューブリン阻害剤
EP1996013A4 (en) * 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
KR101399175B1 (ko) * 2006-07-21 2014-06-19 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 항염증성 및 항알레르기성 시클릭 펩티드
US7585865B2 (en) * 2006-07-21 2009-09-08 The Penn State Research Foundation Protein kinase C zeta inhibition to treat vascular permeability
JP5542064B2 (ja) * 2008-01-22 2014-07-09 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
IT1392567B1 (it) * 2008-12-24 2012-03-09 Bioindustry Park Del Canavese S P A Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario
US20100190691A1 (en) * 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
KR102042015B1 (ko) * 2011-06-13 2019-11-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법

Also Published As

Publication number Publication date
AU2012271781A1 (en) 2014-01-09
JP2014518211A (ja) 2014-07-28
US9248198B2 (en) 2016-02-02
DK2717897T3 (en) 2017-07-17
CA2838662C (en) 2018-07-24
AU2012271781B2 (en) 2017-02-16
EP2717897A2 (en) 2014-04-16
KR102042015B1 (ko) 2019-11-07
PL2717897T3 (pl) 2017-09-29
JP6042425B2 (ja) 2016-12-14
EP2717897B1 (en) 2017-04-19
ES2633343T3 (es) 2017-09-20
WO2012174028A2 (en) 2012-12-20
MX349146B (es) 2017-07-14
KR20140056185A (ko) 2014-05-09
IL229771B (en) 2019-07-31
ZA201309161B (en) 2015-03-25
US8912139B2 (en) 2014-12-16
BR112013032108B1 (pt) 2021-10-26
WO2012174028A3 (en) 2013-02-21
CN103608026A (zh) 2014-02-26
CA2838662A1 (en) 2012-12-20
MX2013014650A (es) 2014-01-24
US20140155314A1 (en) 2014-06-05
EP2717897A4 (en) 2015-01-07
CN106188232A (zh) 2016-12-07
US20140213505A1 (en) 2014-07-31
AU2012271781C1 (en) 2017-09-21
CN106188232B (zh) 2020-01-07
CN103608026B (zh) 2016-08-24

Similar Documents

Publication Publication Date Title
BR112013032108A2 (pt) "composições de peptídeo isolado e usos das referidas composições".
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
DOP2018000020A (es) Tricíclicos sustituidos y método para usarlos
CL2017003226A1 (es) Reguladores nrf2
CL2007002274A1 (es) Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras.
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
AR093355A1 (es) Composiciones y metodos para tratar proteinopatias
WO2014025771A3 (en) Methods and compositions for inactivating enveloped viruses
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
WO2011133890A8 (en) Cns targeting aav vectors and methods of use thereof
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
CL2008000307A1 (es) Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
EA201690541A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
CL2007003765A1 (es) Compuestos derivados de 2-oxo-4-hidroxi-benzotiazol; procesode preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, bronquitis, asma y bronquiectasias.
CL2014003464A1 (es) Método para mejorar la integridad deteriorada de la unión neuromuscular que comprende la administración de una composición que comprende un vector viral adeno-asociado recombinante (raav) que comprende una molécula de ácido nucleico que codifica la alfa-glucosidasa ácida (gaa).
BR112017002781A2 (pt) cassete de expressão aprimorado para acondicionamento e expressão de variantes do fator viii para o tratamento de distúrbios de hemostasia
CL2007003754A1 (es) Compuestos derivados de aril(heteroaril)alquil-amina; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como bronquitis, enfisema pulmonar y epoc.
BR112017023351A2 (pt) composições multidrogas de matriz frágil
WO2012051339A3 (en) Methods and compositions for treating respiratory conditions using platelet enriched plasma
WO2013111012A3 (en) Methods and compositions for therapeutic agents
BR112014011345A2 (pt) partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina
CY1119064T1 (el) Ινωδολυτικες συνθεσεις οι οποιες περιεχουν βρωμελαϊνη και ναττοκιναση για την προληψη και αγωγη φλεβοθρομβωτικων καταστασεων
WO2011066511A8 (en) Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2726 DE 04-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.